Course resources / Citations
Tesamorelin References
Every quantitative claim in this digest traces to one of the sources below — the pivotal RCTs, the meta-analysis, the regulatory record, and the supporting literature.
About this tesamorelin reference list
The tesamorelin references below are the full source list for this digest, numbered to match the inline markers across the research, visceral-fat, dosage, comparison, and FAQ modules. The set spans the pivotal Phase 3 RCTs (NEJM 2007; the 52-week AIDS program), the JAMA 2014 hepatic-fat trial, the JCEM 2011 healthy-men mechanism study, the population-pharmacokinetics analysis, the NIH LiverTox drug-safety monograph, multiple reviews and systematic reviews, a preclinical receptor study, and recent 2024-2026 work including a five-RCT meta-analysis. Each entry carries a DOI or a PubMed link so any claim can be checked at its source.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
- Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
- Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
- Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
- National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): NCBI Bookshelf (NIH); 2018. ↗
- Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Effect of tesamorelin in people with HIV with and without dorsocervical fat: post hoc analysis of phase III double-blind placebo-controlled trial. J Clin Transl Sci. 2023;7(1):e40. ↗
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. ↗
- Sivakumar T, et al. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011;12(8):453-462. ↗
- Fourman LT, Stanley TL, Zheng I, et al. Clinical predictors of liver fibrosis presence and progression in human immunodeficiency virus-associated nonalcoholic fatty liver disease. Clin Infect Dis. 2021;72(12):2087-2094. ↗
- Kanashiro-Takeuchi RM, Takeuchi LM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 2012;109(2):559-563. ↗
- Yen DW, Sherman KE. Causes and outcomes of hepatic fibrosis in persons living with HIV. Curr Opin HIV AIDS. 2022;17(6):359-367. ↗
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
- Russo SC, Ockene MW, Arpante AK, Johnson JE, Lee H, Toribio M, Stanley TL, Hadigan CM, Grinspoon SK, Erlandson KM, Fourman LT. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(11). ↗
- Arora G, Conde KR, Desouza CV. Pharmacologic treatments for the preservation of lean body mass during weight loss. J Clin Med. 2026;15(2):541. ↗
- Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026;54(1):223-229. ↗